MIV THERAPEUTICS INC (OTCBB: MIVT)

Dear Reader,

QUESTION: When is controversy in your industry a good thing? 
ANSWER: When the controversy is about your competitors’ products.

Truth is, often controversy in an industry is a positive element. It signals simultaneously that there is a need for the products that resolve the core needs present product lines and improvement of them.

Enter MIV Therapeutics Inc. (OTCBB:MIVT), a producer of next-generation drug eluting stents. (See Breaking *NEWS* from MIVT Below)

The stent industry, growing along with all the baby boomer-driven healthcare fields, is currently maligned by issues with some of its leading companies.  Both Boston Scientific and Johnson & Johnson have received warning letters from the FDA regarding their stent products.  According to an article in  recently, “the company (Boston Scientific) will be prevented from receiving agency approval of any new models of drug-coated stents” until at least the second half of this year. (See article HERE)

This provides an entry point for MIVT, which offers a drug eluting stent of a different design and application.  MIVT believes its offering solves the prevailing issues of late thrombosis besieging other stents, giving them a flyer into a market estimated at $6 billion per year and growing.  Moreover, MIVT is now generating revenues, they are moving into human trials and MIVT's closest competitor, Conor Medsystems, was just purchased for $1.4 billion by Johnson & Johnson.

If you believe in the baby boomer-driven healthcare sector as we do and are always looking for that corporate window of opportunity to find the next-big-thing, perhaps a brief review of the profile below would be warranted.  
>>>>Spacer>>>

Breaking *News* >From MIV Therapeutics Inc.

Press Release Source: MIV Therapeutics, Inc.
Tuesday October 16, 8:30 am ET

ATLANTA, GA--(MARKET WIRE)--Oct 16, 2007 -- MIV Therapeutics, Inc. (OTC BB:MIVT.OB - News) (Frankfurt:MIV.F - News), a leading developer of next-generation coatings and advanced drug delivery systems for cardiovascular stents and other implantable medical devices, announces that results of the first-in-man safety study with the Company's drug-eluting stent will be presented at the Transcatheter Cardiovascular Therapeutics (TCT) 2007 conference, to be held October 20-25 at the Washington Convention Center in Washington, D.C.

Principal investigator Alexandre Abizaid, M.D., Ph.D., Chief of Coronary Intervention of Institute Dante Pazzanese of Cardiology in Sao Paulo, Brazil, will make the presentation titled, "The MIV Polymer-Free Hydroxyapatite-Coated Sirolimus-Eluting Stent: First-in-Man Angiographic and IVUS Follow-Up Results." Dr. Abizaid's presentation will take place on Sunday, October 21 in Room 152A at 3:03 p.m. Eastern time. It is part of a practical workshop titled "First-In-Man Experiences With Drug-Eluting Stents I and Passive and Active Stent Coatings" within the scientific symposia "Innovative Devices and Futuristic Concepts I: Novel Bare Metal and Drug-Eluting Stents."

"We are very pleased the findings of this important first-in-man study will be presented at such a prestigious medical conference. This 15-patient study was conducted very efficiently, and began with the first human implantation of our low dose polymer-free hydroxyapatite-coated drug-eluting stent in May of this year, and each patient was followed for four months," said Dr. Mark Landy, President of MIV Therapeutics. "We are looking forward to the largest-ever presence for MIV Therapeutics at the TCT conference, we believe that acceptance to present at this conference is an important recognition of the significance of our proprietary technology."

The MIV Therapeutics presence at the 2007 TCT conference also will include two posters:

Presented by Greg L. Kaluza, MD, PhD, Cardiovascular Research Foundation:

"Platelet Activation and Adhesion after Exposure to Nanofilm and Microporous Hydroxyapatite Stent Coating: An Ex-Vivo Study of Hydroxyapatite-Coated Stents Deployed in a Continuous Flow-Chamber Model."

Presented by Dr. Dorna Hakimimehr, Scientist MIVT:

"In-Vitro Evaluation of a Novel Dual-Drug Eluting Stent to Target Inflammation and Proliferation Following Stent Implantation."

Dr. Landy added, "Having completed a $12.55 million equity financing in July, we are looking forward to continuing on our path to commercialize a novel drug-eluting stent without the safety issues surrounding current polymer-based drug-eluting stents."

About Transcatheter Cardiovascular Therapeutics 2007
The Transcatheter Cardiovascular Therapeutics (TCT) conference, sponsored by the Cardiovascular Research Foundation®, is a scientifically stimulating symposium for physicians and other healthcare professionals who specialize in the field of interventional vascular therapy. TCT is the largest interventional vascular medicine symposium in the world, with attendance by more than 10,000 physicians, healthcare providers and industry professionals specialized in the field of interventional vascular therapy. TCT has become the premiere venue to introduce groundbreaking and pioneering innovations in this field. For more information, please visit http://www.tct2007.com.

About MIV Therapeutics
MIV Therapeutics is developing a next-generation line of advanced biocompatible coatings for passive and drug-eluting applications on cardiovascular stents, as well as for a broad range of other implantable medical devices. The Company's ultra-thin coating formulation is designed to protect surrounding tissue from potentially harmful interactions with bare metallic stents. This coating platform is derived from hydroxyapatite (HAp), an organic material that has demonstrated excellent in vivo safety and biocompatibility. Hydroxyapatite is a porous material that makes up the bone mineral and matrix of teeth, and is widely used today as a bone substitute material and for coatings on implantable fixation devices in orthopedic, dental and other applications. The Company's novel polymer-free drug-eluting technologies based on HAp could also provide an attractive alternative to current polymer-based drug-eluting coatings on the stent market, which have been associated with undesirable effects. The Company's drug-eluting coatings are additionally designed to suit a broad range of implantable medical devices that could benefit from highly customizable drug release profiles. MIV Therapeutics has a Collaborative Research Agreement with the University of British Columbia and has received a government grant for its research program on the "Development of Novel Drug Eluting Composite Coatings for Cardiovascular Stents," under the National Research Council-Industrial Research Assistance Program. Under this sponsorship, the Company is expected to complete its drug-eluting research and development program and to reach product commercialization. MIV's intellectual property portfolio includes patents held by the University of British Columbia and exclusively licensed to MIV. Key patent applications filed simultaneously in various countries around the world further protect the commercial exclusivity of MIV's inventions in the global marketplace. For more information, please visit www.mivtherapeutics.com.

Forward-Looking Statements
Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements. Such statements are indicated by words or phrases such as "proposed," "expected," "believe," "will," "breakthrough," "significant," "indicated," "feel," "revolutionary," "should," "ideal," "extremely" and "excited." These statements are made under "Safe Harbor" provisions of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those described in forward-looking statements and are subject to risks and uncertainties including, without limitation, the potential for the unsuccessful closing by the Company of its Vascore acquisition, together with the raising of funding sufficient to continue with its operations and those contemplated by the Company as a consequence thereof, and the ability of the Company to raise sufficient funding and to continue to develop its various business interests as presently contemplated. See the Company's filings with the Securities and Exchange Commission including, without limitation, the Company's recent Form 10-K and Form 10-Qs, which identify specific factors that may cause actual results or events to differ materially from those described in the forward-looking statements.

Contact:
   
     MIV Therapeutics Inc.
     Anthony L Huston
     Director of Investor Relations
     (604) 301-9545, x14
     (800) 221-5108
     ahuston@mivtherapeutics.com
     investor@mivtherapeutics.com
      
     Lippert/Heilshorn & Associates, Inc.
     Kim Sutton Golodetz
     (kgolodetz@lhai.com)
     Emmanuelle Ferrer
     (eferrer@lhai.com)
     (212) 838-3777     

Source: MIV Therapeutics, Inc.
>>>Spacer>>>

About MIV Therapeutics Inc.

MIV Therapeutics Inc., ("MIV") ("MIVT") is focused on commercializing the next generation of fully biocompatible coatings for cardiovascular stents and drug delivery systems to treat coronary artery disease, an estimated $6 billion worldwide market. MIVT’s uniquely biocompatible drug delivery technologies for cardiovascular stents are designed to offer a safer alternative to current drug-eluting stents and to solve the issues of late thrombosis. 

MIV has recently acquired Biosync Scientific in India and earlier, SagaX in Israel to significantly expand product offerings, as well as design, manufacturing and distribution capabilities.

Working since 2001 in close collaboration with The University of British Columbia (UBC), MIVT has developed a unique biocompatible nano-film coating that eliminates the side-effects attributed to current stent technology. This is a major breakthrough, which utilizes Hydroxyapatite (HAp), a mineral and major component of human bones and teeth, to protect surrounding arterial tissue from direct contact with bare metal stent. Comprehensive animal studies demonstrated Hydroxyapatite improves the performance of bare metal stents by inhibiting inflammatory responses, a common cause of restenosis, a re-growth of vascular tissue following stent implantation. 

MIVT announced the first ever human implantation of a hydroxyapatite-coated stent and the launch of the MIVT Pilot Trial.  The MIVT Pilot Trial will evaluate the safety and efficacy of MIVT’s polymer-free nanoscale microporous hydroxyapatite drug-eluting stent for the treatment of single de novo lesions in native coronary arteries.  The first procedure was conducted by Dr. Alexandre Abizaid of Institute Dante Pazzanese of Cardiology in Sao Paulo, Brazil. Dr. Abizaid and Institute Dante Pazzanes of Cardiology are among the world’s foremost experts in conducting clinical trials researching both new and existing drug-eluting stents.  MIV Therapeutics announced on May 31, 2007: 

Start of Clinical Trial Marking First Ever Human Implantation of A Hydroxyapatite Coated Stent

The trial to study safety and efficacy of one of the company’s proprietary polymer – free drug eluting stent technologies

The beginning of human implantation represents the culmination of extensive research and development and a successful animal trial program. Human implantation represents a crucial milestone in MIVT’s strategic plan to develop a new class of polymer-free drug-eluting stents that could provide patients with superior outcomes.  "We are very pleased to announce that our human trials are underway in-line with our previous guidance," said Dr. Mark Landy, President of MIV Therapeutics. "We have worked diligently to create a new, novel technology that we expect will be an excellent alternative for millions of patients around the world suffering from coronary artery disease.

MIV Therapeutics is focused on commercializing the next generation of fully biocompatible coatings for cardiovascular stents and drug delivery systems to treat coronary artery disease, an estimated $6 billion worldwide market. The company's technologies are expected to offer a safer alternative to current drug-eluting stents and hope to solve the issues of late thrombosis.

MIVT’s polymer-free nanoscale microporous hydroxyapatite drug-eluting stent uses the Company’s GenX coronary stent system. The GenX stent is coated with one of MIVT’s proprietary hydroxyapatite polymer-free drug eluting systems that is 700 nanometers thin. 

This technology is not limited to stents and can be used on any implantable medical device including those in the orthopedic field. MIV also has a number of Non-Polymeric drug eluting coatings currently under development that are expected to offer a safer and possibly more effective solution to current products on the market. Human implantation of these technologies is also expected in 2007. 

The Biosync Scientific acquisition brings MIVT several innovative interventional cardiology products including the GenX CrCo coronary stent system, the GenX stainless steel coronary stent system, the X-ACT Inflation Device, a haemostatic y-connector adaptor kit, an insertion tool, a guide wire torquer and a high-pressure 3-way stopcock, all of which are CE Mark-certified and ready for immediate use in Europe and other countries around the world where the CE Mark is recognized. MIVT will use the Biosync stent platform as the underlying bare-metal stent platform for its proprietary biocompatible polymer-free next generation drug-eluting stents. 

SagaX, located in Israel, is a developer of advanced biomedical technologies, including  stroke-prevention devices.  Its novel Aortic Embolic Protection Device (AEPD) is a unique, proprietary filter/deflector device designed to prevent cardio embolic stroke following heart surgery. SagaX is also developing further generations of anti-embolic devices. 
 

In 2006, MIVT proudly announced its nomination to the "NANOTECH Top 100", presented by the International Association of Nanotechnology (IAnano) and FORTUNE Magazine featuring the leading 100 public nanotech companies worldwide, another public acknowledgment of the importance of MIVT’s advanced technology and development programs.  The article was published in the FORTUNE 500 April 2006 issue. 

MIVT announced that a recent company sponsored bench test confirmed that merging Biosync Scientific's certified bare metal stent platform with the Company's polymer-free drug delivery system met critical "FDA Draft Guidance for the Submission of Research and Marketing Applications for Interventional Cardiology Devices" requirements for in vitro fatigue testing.

MIVT’s current product portfolio encompasses the following preclinical development projects:

HAp-nano-film coating technology. MIVT's lead product in development is an HAp-coated coronary stent with a nano-film coating. HAp is naturally found in bone and tooth enamel and demonstrates complete biocompatibilty with the human body. As such, it may inhibit a variety of adverse and inflammatory reactions and potentially help reduce restenosis, a recurrence of CAD, Coronary Artery Disease, a re-blocking of arteries following angioplasty. It is also believed that HAp-coated cardiovascular stents, unlike their counterparts available at the global markets at the present time, will not trigger late adverse thrombogenic reactions. 

Drug-eluting stents. MIVT is expected to enter the drug-eluting stent market by using a thicker coating of HAp loaded with a suitable drug, i.e. anti-inflammatory. The technology has a variety of potential applications in cardiovascular and non-cardiovascular drug/device combination products, including peripheral stents, biodegradable implants, gene therapy, and delivery systems for release of chemotherapeutic agents. 

MIV Therapeutics, Inc. was incorporated in Nevada in 1999.  Beyond SagaX in Israel and Biosync in India, the Company has corporate offices in Atlanta, GA, USA and a wholly-owned subsidiary, MIV Technologies Inc. (MIVI), a manufacturing and research and development arm in Vancouver, Canada. MIVI’s 17,000 square foot manufacturing and office facility in Vancouver, British Columbia, including a 1,000 square foot "Class 10,000" controlled environment room facility is suitable for production of both the MIVI laser-cut stent and the coated stents. MIVI may also act as a subcontractor providing know-how and specialized HAp coating services for third parties that may be interested in commercialization of their own products in HAp-coated version. 
>><Spacer>>>

Marketing

IRVINE, Calif., April 9, 2007 (PRIME NEWSWIRE) -- "As most small cap investors are neither medical doctors or biotechnology scientists, a critical element in the evaluation of a company is the progress made toward Food and Drug Administration approvals,'' stated SmallCap Sentinel analyst D.R. Clark. "And sometimes companies give investors a glimpse of their potential FDA future.''

"For example, MIV Therapeutics Inc. (OTC BB:MIVT.OB), a leading developer of next-generation biocompatible coatings and advanced drug delivery systems for cardiovascular stents and other implantable medical devices, just announced that a recent company-sponsored bench test confirmed that merging Biosync Scientific's certified bare metal stent platform, which MIVT recently acquired, with the company's polymer-free drug delivery system met critical 'FDA Draft Guidance for the Submission of Research and Marketing Applications for Interventional Cardiology Devices' requirements for in vitro mechanical fatigue testing,'' Clark noted. "Clearly, this is a strong indicator."

Coronary stenting is a key component of interventional cardiology.  This is a rapidly growing clinical specialty and one characterized by the ready adoption of new products. The coronary stent market recorded worldwide sales of over USD$5 billion in 2006 and is expected to reach USD$6 billion in 2007. 

Additionally, through the diversification of its product/technology portfolio, MIV Therapeutics hopes to also capitalize on new applications of its technology in order to access the USD$200 billion market of drug/device combination products.  The market for drug-eluting stents is one of the fastest growing segments within the medical device arena, with annual growth approaching 25%.

Heart Disease Facts: Why it Gets the Attention

• Statistically, heart disease is the number one cause of mortality in North America
• 64 million-plus Americans suffer from cardiovascular disease
• Americans suffer over 1,000,000 known heart attacks each year
• Heart Disease and related care account for $329.2 billion and growing
• Women believe the greatest threat to their health is breast cancer (In reality, they are five times more likely to die of heart disease).

Other companies involved in stent and medical bio-nano technology include: 

JOHNSON & JOHNSON [NYSE: JNJ] OSCIENT PHARMACEUTICAL [Nasdaq: OSCI] PROVECTUS PHARMA [OTCBB: PVCT] ACETO CP [NASDAQ: ACET]  ELI LILLYCO [NYSE: LLY] PFIZER INC [NYSE: PFE] 
GLAXOSMITHKLINE PLC [NYSE: GSK] NOVARTIS AG ADS [NYSE NVS] MEDTRONIC INC [NYSE:MDT]
MERCK CO INC [NYSE: MRK] BOSTON SCIENTIFIC [NYSE:BSX]

Intellectual Property

Effective protection of intellectual property and continual patent development provide a foundation for MIV Therapeutics’ past and future successes.  MIV’s proprietary technologies are well protected by in excess of 50 US and foreign patents and patent applications in appropriate international markets.  MIV has exclusive worldwide rights to the HAp coating technology from The University of British Columbia (UBC) for use on stents and other medical devices, including the rights to manufacture and market coated products using these technologies. 

To date, The UBC has filed a number of patent applications on novel coating technologies that MIV intends to use for its stent coating and for additional medical devices. 

MIVT has completed a comprehensive range of biocompatibility tests and preliminary animal trials on the HAp coating technology.  Results from these tests consistently confirm exceptional suitability of HAp as a very solid candidate for effective and side-effect-free coating for coronary stents and other implantable medical devices. 

• MIVT HAp coating passed with flying colors demanding mechanical testing including fatigue life test simulating 10 years of continuous use on cardiovascular stents (Enduratec)
• MIVT HAp coating does not result in thrombosis (blood clotting) (Toxicon) 
• NSERC sponsored, Drug-eluting Stent Coating R&D program
• Development of two alternative coating technologies 
• In vivo Safety Studies: MIVT stent coating is safe and did not cause any adverse arterial response (DISA Vascular is South Africa and The Methodist, Houston, USA) 

HAp coated stent considered non-mutagenic HAp coated stent considered non-clastogenic HAp coated stent is considered non-hemolytic HAp coated stent considered non-cytotoxic HAp coated stent is considered negligible irritant HAp coated stent elicited no allergic reaction HAp coated stent is considered non-pyrogenic HAp coated stent was non- toxic

Preclinical results support the expectation that biological performance of MIVT’s proprietary HAp-coated stents may match and exceed performance of currently available stents, without adverse effects such as thrombogenicity or long-term restenosis.   Porcine trials completed in 2005 at the Methodist Hospital and Texas Heart Institute confirmed that MIVT's HAp coating is safer and an excellent candidate for drug eluting coated stents. The most important finding from this study is that the hydroxyapatite stent coating presents itself as uniquely biocompatible by comparison to polymeric stent coatings. 

• MIVT aims to be the dominant force in the worldwide interventional cardiology market by developing the safest product with superior efficacy that meaningfully improves the lives of those touched by coronary artery disease 

• MIVT strategy is to quickly build a presence in the Emerging Markets with a suite of competitive generic products and to follow up with differentiated novel products that can be sold worldwide

• With the current letters of intent and option agreements MIVT has: 
• an unmatched pipeline of unique polymer free pro healing drug delivery systems that promote epithelial growth and do not cause excessive injury, inflammation or thrombosis
• Access to drugs that do not infringe upon the intellectual properties of others
• Competitive bare metal stent platforms
• Proven generic drug eluting stent technology 
• A broad suite of ancillary interventional cardiovascular products
• Strong representation in Europe and the Emerging Markets

MIVT’s Nano-film HAp coating can reduce post-procedural trauma and eliminate undesirable long-term side effects. A multi-layer electro-chemically deposited porous HAp coating, which is already at an advanced development stage, can be loaded with a considerable quantity of drugs, including anti-inflammatory, immune system depressants, or with the new generation of antithrombotic and/or antirestenotic drugs. 

The Company’s first commercial product could be a passive HAp-coated coronary stent for use in angioplasty procedures followed by additional stent products for drug-elution and for peripheral arteries. Drug-eluting stents have gained significant popularity among the professional medical community and investors alike.  MIVT’s goal is to clearly position itself among the leaders in the lucrative drug-eluting stent market by bringing to market a product that is safer than what is currently available without compromising required efficacy and long-term durability. 
 

Drugs are contained in "nano-chambers", size of which can be controlled between a few nanometers and several micrometers in diameter to suit specific drug release requirements. Multilayer composite coating technologies may combine advantages of HAp passive coatings with those of polymer-free, liposome technologies for improved biocompatibility, enhanced mechanical and controlled drug eluting characteristics. 

The Company’s lead product in development is a passive, nano-film Hydroxyapatite (HAp) coating.  In parallel, the Company is developing a multi-layer nano-film coating with drug-eluting capabilities to facilitate therapeutics and treatments for localized drug delivery systems. 

HAp is naturally found in bone and tooth enamel and maintains friendly co-existence with human body.  Numerous results from clinical tests and surgical practice have shown that in addition to its demonstrated biocompatibility, this new generation of advanced biocompatible coatings is non-toxic and does not induce thrombogenicity, long-term restenosis, allergic or inflammatory reactions, therefore making it a solid candidate as a coating for coronary stents and other implantable medical devices. 

MIVT’s HAp coating technology has demonstrated that it can meet the stringent technical requirements for use on cardiovascular stents.  The coating technology has successfully progressed through a comprehensive range of animal and mechanical trials required for CE Mark and FDA approvals in both Europe and the US.  These include thrombogenicity (blood clotting), cytotoxicity, and demanding fatigue life testing for its nano-film HAp-coated coronary stent. The results support the expectation that the HAp-coated stent may be considerably safer than currently available bare stents. 

The HAp coating technology is being developed in a series of R&D phases in a collaboration between  MIV Therapeutics and The UBC Metals and Materials Ceramics Section research group. 

Since patients receiving stents remain at risk for the aforementioned problems, doctors continue to explore more efficient and longer-lasting stenting solutions. One of the more effective methods involves employing stents that are covered with medicines that can be released once inside the body.  These are called drug-eluting stents. MIVT is in a solid position to enter the lucrative drug-eluting stent market using two product development approaches: 

Nano-film coating which can reduce post-procedural trauma; and Porous HAp coating, which can be loaded with considerable quantity of drugs, including new generation of anti-inflammatory drugs, immune system depressants, or with the new generation of antithrombotic and/or antirestenotic drugs. This technology has applications in cardiovascular and non-cardiovascular drug/device combination products, including peripheral stents, biodegradable implants, gene therapy, and delivery systems for release of chemotherapeutic agents. 

Drug-eluting stents countermeasure post-deployment inflammatory reactions and considerably reduce the incidence of restenosis to approximately 8% from 25% experienced with bare stents. Drug-eluting stents have become, after only one year on the market, the most widely used modality for coronary revascularization. This has resulted in a paradigm shift in clinical practice that has quickly become the standard of care, despite the fact that drug-eluting stents cost in excess of $2,000—three to four times the price of a bare metal stent.  Recent long-term data showing that some patients may suffer thrombosis after the angioplasty has lead to a search for a safer alternative to the current polymer coated stents.  MIVT is well positioned to provide that much needed safer solution.  Human Trials started in the first half of 2007.

Recent News From MIVT

Press Release Source: MIV Therapeutics, Inc.
Thursday September 27, 2:00 am ET

ATLANTA, GA--(MARKET WIRE)--Sep 27, 2007 -- MIV Therapeutics (OTC BB:MIVT.OB - News) (Frankfurt:MIV.F - News), a leading developer of next-generation coatings and advanced drug delivery systems for cardiovascular stents and other implantable medical devices, today announced a research collaboration with contributions in kind from both Smith & Nephew and MIV Therapeutics to develop new coatings and drug delivery systems for orthopedic devices.

"We are honored to be working with Smith & Nephew, an established market leader in orthopedics and look forward to a long and prosperous relationship," said Mark Landy, President of MIV Therapeutics. "We have worked diligently to develop a product pipeline with multiple applications in multiple therapeutic disciplines and this collaboration is proof thereof. We now have programs in cardiology and orthopedics, and will continue to evaluate additional opportunities in different therapeutics areas."

You may view the entire news release HERE

Press Release Source: MIV Therapeutics Inc.
Thursday July 19, 3:30 am ET

ATLANTA--(BUSINESS WIRE)--MIV Therapeutics Inc. (OTCBB:MIVT - News; FWB:MIV), a leading developer of next-generation biocompatible coatings and advanced drug delivery systems for cardiovascular stents and other implantable medical devices, invites investors to view a transcript of the Company's recent investor conference call, during which President Dr. Mark Landy recapped the Company's major achievements for the first half of 2007 and detailed the Company's strategic initiatives for the year ahead and beyond.

"The first half of 2007 has been a transforming period for us," said Dr. Landy. "We have turned MIVT from a coating company into a full-fledged stent company with a very unique and valuable technology that can be applied to stents and other medical devices."

MIVT is developing a next-generation cardiovascular stent technology being designed to provide substantial health and safety benefits and outcomes over previous generations of drug-eluting stents. MIVT has developed a new line of both ultra-thin and drug-carrying cardiovascular stent coatings based on its proprietary hydroxyapatite (HAp) technology.

During the conference call, Dr. Landy provided investors with a brief overview of the current state of the estimated $6 billion market for cardiac stents. Dr. Landy commented, many physicians he comes in contact with are very excited with the prospect for a new, safer, drug-eluting stent, so they once again can offer patients a product that significantly reduces the chance of having to have a repeat procedure. "This is exactly where MIVT has the opportunity to revolutionize the drug-eluting stent industry and make a difference," said Dr. Landy.

You May View The Entire Release HERE

ATLANTA--(BUSINESS WIRE)--MIV Therapeutics Inc. (OTCBB:MIVT - News; FWB:MIV), a leading developer of next-generation biocompatible coatings and advanced drug delivery systems for cardiovascular stents and other implantable medical devices, has announced the online availability of an updated Investor Fact Sheet detailing the Company's high-growth business model, as well as recent strategic achievements, including the recent acquisition of India-based Biosync Scientific, along with eight CE-marked products and a world-class senior management team and advisory board.

You May View The Entire Release HERE

ATLANTA--(BUSINESS WIRE)--MIV Therapeutics Inc. (OTCBB:MIVT - News; FWB:MIV), a leading developer of next-generation biocompatible coatings and advanced drug delivery systems for cardiovascular stents and other implantable medical devices, has announced the addition of a portfolio of new cardiovascular stents and related products, which have already been CE-marked for commercialization in several multibillion dollar markets, including Europe, Asia and India.

You May View The Entire Release HERE

ATLANTA--(BUSINESS WIRE)--MIV Therapeutics Inc. (OTCBB:MIVT - News; FWB:MIV), a leading developer of next-generation biocompatible coatings and advanced drug delivery systems for cardiovascular stents and other implantable medical devices, today announced that a recent Company sponsored bench test confirmed that merging Biosync Scientific's certified bare metal stent platform, which MIVT recently acquired, with the Company's polymer-free drug delivery system met critical "FDA Draft Guidance for the Submission of Research and Marketing Applications for Interventional Cardiology Devices" requirements for in vitro mechanical fatigue testing.

You May View The Entire Release HERE
<<<Spacer>>>

Financial Highlights For  MIVT

• MIVT’s biocompatible stents matched or outperformed J&J’s world’s leading drug-eluting Cypher stent in key categories when tested in animal model at the Erasmus University in Rotterdam, The Netherlands.

• MIVT recently began human implantation of its HAp nano-film coated stents, scheduled to begin early 2007 

• Biosync has a strong portfolio of CE-marked products already approved for use in Europe and India, among other places 

The unique value proposition of  is that it is now in late-stage development of completely new, proprietary, exceptionally biocompatible coatings for stents and polymer-free stent drug delivery systems using hydroxyapatite (HAp) – an entirely new generation of advanced coating technologies for stents unique to MIV Therapeutics.

• Efficacy of drug-eluting stents has led to increased adoption by physicians

• Huge market – the total cardiovascular stent market is expected to expand from approximately $3 billion in 2004 to $6 billion in 2007

• Drug/device products have gained significant popularity and represent approximately 70% of the market

The downside of cardiovascular stents, however, is that they are made of metal, and the exposure of the metal to the artery can cause a negative reaction that can lead to reblockage of the artery (restenosis). To combat this problem, companies like Johnson & Johnson have enjoyed tremendous market success by developing polymer-based stent coatings that carry drugs to treat such localized reactions and have achieved some degree of success in lowering restenosis rates.  But these have had issues also, and MIVT’s breakthrough polymer-free drug-eluting stents offer a truly next-generation solution. 
 

Dr. Mark Landy - President
Dr. Landy is widely recognized for his financial acumen and proven accomplishments as a Wall Street equity analyst with diverse sell-side, buy-side and venture capital experience. He most recently distinguished himself as the Senior Research Analyst of Medical Supplies and Devices at Susquehanna Financial Group, where he was voted the firm’s top-ranked healthcare analyst by institutional clients in both 2004 and 2005.In addition, Dr. Landy is a familiar financial pundit in the financial media, who has made frequent appearances on CNBC, Reuters, Dow Jones, Bloomberg, and in The Wall Street Journal and Business Week, among other outlets. Mr. Landy holds a degree in business from the Wharton School of Business at the University of Pennsylvania.

Alan P. Lindsay, Chief Executive Officer, and Director 
Mr. Lindsay has been Chairman, President, Chief Executive Officer, and Director of MIVT since October 2001. He has experience in building and directing public companies for the past 15 years. From 1991 to 2000, Mr. Lindsay was Chairman, President and Chief Executive Officer of a base metals exploration company that he co-founded and took public on the Toronto (TSX) and American Stock Exchange (AMEX). Mr. Lindsay was also Chairman of the Board of GeneMax Pharmaceuticals Inc., a company he co-founded in 1999. 

Patrick A. McGowan, Executive Vice President, Chief Financial Officer, and Director
Mr. McGowan has extensive experience in senior management in both private and public companies. At MIVT, he oversees daily operations and manages corporate matters, which include regulatory filings, strategic planning, and negotiations with legal counsel, auditors, and financial institutions. Mr. McGowan has previous management experience with Flecto Company and McNeil Laboratories, a subsidiary of Johnson & Johnson, where he was a member of the team that introduced Tylenol, anesthetic and psychotropic drugs to the market. 

Tom Troczynski, Ph.D., PEng, Vice President, Coating Technologies
Dr. Troczynski joined MIVT in February 2002 to assist in the development of its proprietary coating technology. His primary area of research is ceramics, in particular bioceramics, and he has focused on the development of biocompatible HAp coatings for metallic substrates, such as medical devices, implants, and stents. Dr. Troczynski is a professor of ceramics at The University of British Columbia in the Department of Materials Engineering. He obtained a Ph.D. in materials science and engineering from McMaster University in Hamilton , Ontario in 1987. He has authored many articles in professional journals and has filed a number of patents. Dr. Troczynski is a recognized authority in the field of ceramics and ceramic coatings and is a frequent lecturer at international symposia and scientific forums.

Wilbert Keon, OC, M.D., FRCSC, Chair of Scientific Advisory Board
Dr. Keon is Chairman of the Scientific Advisory Board. He is the founder of the University of Ottawa Heart Institute, an international center for cardiac care, research, and education with a clinical budget of over $80 million. During his tenure at the University of Ottawa Heart Institute, Dr. Keon established international standards in clinical program delivery, cardiac facilities design, public and professional education programs, and research and technology development. Dr. Keon’s career has drawn research grants totaling $66 million. He has many clinical innovations, among them, his pioneering work on surgical reperfusion in acute heart attacks, the first cardiac transplant in Ottawa, the first use of the Jarvik 7-70 artificial heart in Canada, and the first Canadian infant heart transplant. 

Arun Chockalingam, BE, MS, Ph.D, FACC, FACEP, Special Advisor, Scientific & International Affairs
Dr. Chockalingam is a Clinical Professor of Health Care and Epidemiology at UBC. He holds degrees in electronics engineering, biomedical engineering, and medicine. He is an author, educator, lecturer, and internationally recognized cardiovascular expert. Dr. Chockalingam received the Dr. Harold N. Segall award of Merit from the Canadian Cardiovascular Society for outstanding contributions to the progress of cardiovascular disease prevention in Canada. The American College of Cardiology presented him with an honorary fellowship in March 2000. Dr. Chockalingam has authored or co-authored over 100 scientific/medical publications. 

Daniel Savard, University of Montreal, Cardiology Clinical, Canada
Dr. Savard has more than 20 years of clinical practice and research experience as a cardiologist. He is a professor of medicine at the University of Montreal. Dr. Savard has participated in more than 40 clinical trials and international multicenter studies and has published dozens of manuscripts. His research areas include coronary heart disease, congestive heart failure, arterial hypertension, and angiogenesis therapy in congestive heart failure. He has been a member of several large pharmaceutical clinical advisory boards including Pfizer Inc. (PFE-NYSE), Aventis SA (AVE-NYSE), Biovail Corp. (BVF-NYSE), and Crystaal Corporation. He currently consults for Biovail and Medisys PLC (MDIYF.PK).a

Dr. Greg L. Kaluza, M.D., Ph.D, F.A.C.C., 
Dr. Greg L. Kaluza, M.D., Ph.D, F.A.C.C. is a widely recognized expert in the field of interventional cardiology. He has joined the company’s Scientific Advisory Board, where he will help guide the company’s clinical trials and other key research programs. Dr. Kaluza is Scientific Director of the Center for Research in Cardiovascular Interventions (CRCI) at the Methodist Hospital Research Institute in Houston , Texas . The CRCI is a multifaceted, highly specialized group focused on research in interventional cardiology. The CRCI includes an experimental animal laboratory, a cardiovascular angiographic analysis core, and a clinical research department.
<<<Spacer>>>

To Contact MIV Therapeutics

---

*** The Bull is Running. ***
There may never be a better time to feature YOUR company
to over 1 MILLION investors.

To learn more about our programs email us directly at info@stockupticks.com

Disclaimer: StockUpTicks.com is a property of Market Pathways Financial Relations Incorporated (MP).  The information, opinions and analysis contained herein are based on sources believed to be reliable but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. Past performance is no guarantee of future results. This report is a paid advertisement and is for information purposes only and should not be used as the basis for any investment decision.  MP has been paid twenty four thousand dollars by MIV Therapeutics Inc. for preparation and distribution of this report and other advertising services over a ninety day period. This constitutes a conflict of interest as to MP’s ability to remain objective in its communication regarding the subject company.  Write or call MP for detailed disclosure as required by Rule 17b of the Securities Act of 1933/1934 - Market Pathways 17595 Harvard Ave., Suite C519 Irvine, CA  92614.  MP is not an investment advisor and this report is not investment advice. This information is neither a solicitation to buy nor an offer to sell securities but is a paid advertisement.  Information contained herein contains forward-looking statements and is subject to significant risks and uncertainties, which will affect the results.  The opinions contained herein reflect our current judgment and are subject to change without notice. MP and/or its affiliates, associates and employees from time to time may have either a long or short position in securities mentioned.  Information contained herein may not be reproduced in whole or in part without the express written consent of Market Pathways Financial Relations Incorporated.